全文获取类型
收费全文 | 8267篇 |
免费 | 764篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 76篇 |
儿科学 | 344篇 |
妇产科学 | 136篇 |
基础医学 | 1274篇 |
口腔科学 | 169篇 |
临床医学 | 914篇 |
内科学 | 1620篇 |
皮肤病学 | 85篇 |
神经病学 | 649篇 |
特种医学 | 540篇 |
外科学 | 1039篇 |
综合类 | 174篇 |
一般理论 | 4篇 |
预防医学 | 802篇 |
眼科学 | 125篇 |
药学 | 484篇 |
中国医学 | 19篇 |
肿瘤学 | 587篇 |
出版年
2021年 | 118篇 |
2020年 | 88篇 |
2019年 | 114篇 |
2018年 | 170篇 |
2017年 | 90篇 |
2016年 | 143篇 |
2015年 | 139篇 |
2014年 | 175篇 |
2013年 | 265篇 |
2012年 | 358篇 |
2011年 | 385篇 |
2010年 | 227篇 |
2009年 | 224篇 |
2008年 | 292篇 |
2007年 | 371篇 |
2006年 | 374篇 |
2005年 | 303篇 |
2004年 | 292篇 |
2003年 | 268篇 |
2002年 | 275篇 |
2001年 | 258篇 |
2000年 | 259篇 |
1999年 | 184篇 |
1998年 | 122篇 |
1997年 | 121篇 |
1996年 | 113篇 |
1995年 | 97篇 |
1994年 | 113篇 |
1993年 | 120篇 |
1992年 | 159篇 |
1991年 | 163篇 |
1990年 | 156篇 |
1989年 | 195篇 |
1988年 | 186篇 |
1987年 | 221篇 |
1986年 | 170篇 |
1985年 | 167篇 |
1984年 | 132篇 |
1983年 | 121篇 |
1982年 | 68篇 |
1981年 | 75篇 |
1980年 | 78篇 |
1979年 | 77篇 |
1978年 | 80篇 |
1977年 | 70篇 |
1976年 | 71篇 |
1975年 | 66篇 |
1974年 | 72篇 |
1973年 | 80篇 |
1971年 | 65篇 |
排序方式: 共有9041条查询结果,搜索用时 31 毫秒
1.
Jennifer Margaret Roberts Dorothy A. Machalek Bethan C. Butler Joanne Crescini Suzanne M. Garland Annabelle Farnsworth 《International journal of cancer. Journal international du cancer》2023,152(8):1593-1600
In Australia's HPV-based cervical screening program, we previously showed that risk of histological high-grade abnormality at 1 year post screening decreased with age in women with oncogenic HPV. In this study, we followed 878 HPV16/18 positive women aged 55 years and over for up to 3 years post screening test, to determine the proportion with histological high-grade abnormality (HGA, incorporating high-grade squamous intraepithelial abnormality (HSIL), adenocarcinoma in situ (AIS), squamous cell carcinoma (SCC) and adenocarcinoma) and to correlate risk of HGA with liquid-based cytology result and with prior screening history. HGA was detected in 7.8% at 1 year and 10.0% at 3 years, with no significant difference (P = .136), despite the number of women with follow-up information significantly increasing from 82.9% to 91.0% (P < .0001). The proportion of HPV16/18 positive women with HGA at 3 years was highest in those with an HSIL cytology result (79.0%) and lowest in those with negative cytology (6.2%). Women with an adequate screening history had fewer HGA than such women with inadequate prior screening (6.6% vs 16.0%, P = .001) or with a history of an abnormality (6.6% vs 14.4%, P = .001). HPV16/18 infection in women over 55 years may have a different natural history from that in younger women, in whom HGA are more common after HPV16/18 detection. In HPV-based cervical screening programs, management algorithms for screen-detected abnormalities based on risk stratification should include factors such as age, screening history and index cytology result, so that women receive appropriate investigation and follow-up. 相似文献
2.
3.
4.
5.
Javed Butler Mei Yang Massimiliano Alfonzo Manzi Gregory P. Hess Mahesh J. Patel Thomas Rhodes Michael M. Givertz 《Journal of the American College of Cardiology》2019,73(8):935-944
Background
Epidemiology of patients with worsening heart failure and reduced ejection fraction (HFrEF) in the real-world setting is not well described.Objectives
The purpose of this study was to describe incidence, clinical characteristics, treatment, and outcomes of patients with HFrEF who develop worsening heart failure (HF) in the real-world setting.Methods
Data on patients with incident HFrEF from the National Cardiovascular Data Registry PINNACLE were linked to pharmacy, private practitioner, and hospital claims databases. Incidence, clinical characteristics, treatment (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist) and outcomes of patients with worsening HF, defined as ≥90 days of stable HF with subsequent worsening requiring intravenous diuretic agents, were assessed.Results
Of 11,064 HFrEF patients, 1,851 (17%) developed worsening HF on average 1.5 years following initial HF diagnosis. Patients who developed worsening HF were more likely to be African American, be octogenarians, and have higher comorbidity burden (p < 0.001). At the onset of worsening HF, 42.4% of patients were on monotherapy, 43.4% were on dual therapy, and 14.1% were on triple therapy. A total of 48%, 61%, and 98% of patients were on >50% target dose for angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist, respectively. The 2-year mortality rate was 22.5%, and 56% of patients were rehospitalized within 30 days of the worsening HF event.Conclusions
In the real-world setting, 1 in 6 patients with HFrEF develop worsening HF within 18 months of HF diagnosis. These patients have a high risk for 2-year mortality and recurrent HF hospitalizations. The use of standard-of-care therapies both before and after the onset of worsening HF is low. With high unmet medical need, patients with worsening HF require novel treatment strategies as well as greater optimization of existing guideline-directed therapy. 相似文献6.
7.
8.
9.
10.